Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140941 | 0.78 | LATS1 (0.38) | LATS1LATS2 | |
| Hydrochloric Acid SCHEMBL1490938 | 0.74 | ALDH1A1 (0.35) | — | |
| SCHEMBL1140601 | 0.73 | LATS1 (0.40) | LATS1LATS2 | |
| SCHEMBL3864507 | 0.73 | DYRK1A (0.32) | — | |
| SCHEMBL1141204 | 0.72 | LATS1 (0.40) | LATS1LATS2 | |
| SCHEMBL1140809 | 0.71 | LATS1 (0.38) | LATS1LATS2 | |
| Methylene Chloride SCHEMBL1141088 | 0.71 | LATS1 (0.38) | LATS1LATS2 | |
| SCHEMBL1141154 | 0.69 | PIK3CD (0.34) | LATS1LATS2 | |
| SCHEMBL1141001 | 0.68 | KDM4E (0.36) | LATS1LATS2 | |
| SCHEMBL3178388 | 0.68 | MAPK1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897609-B2 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219228-A1 | Aryl substituted imidazonaphthyridines | IL2, IRF3, EIF2AK2 | LATS1 3526/4885LATS2 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.